Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) is a transaction notification dated June 11, 2025, covering the month of June 2025. The report discloses a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) rather than providing general corporate financial results.
Key Financial Metrics
The filing does not contain consolidated revenue, profit, cash flow, margin, debt, or liquidity metrics for GSK plc. It solely reports on a single insider transaction:
- Instrument: Ordinary Shares of 31 pence each (ISIN: GB00BN7SWP63).
- Transaction Type: Sale.
- Volume: 30,000 shares.
- Price: £15.0724 per share.
- Total Value: Approximately £452,172 (calculated from volume and price).
- Date: June 9, 2025.
- Venue: London Stock Exchange (XLON).
Material Changes
The filing does not provide comparative financial data or material changes to the company's operational performance versus prior periods. The only reported change is the reduction of the PDMR's personal shareholding.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or contingencies related to GSK's business operations. It is a regulatory disclosure of a specific trade executed by an executive.
Important Facts for Investors
- Executive Identity: The seller is James Ford, SVP and Group General Counsel, Legal and Compliance.
- Transaction Nature: This is an initial notification of a sale of 30,000 ordinary shares.
- Market Price: The transaction occurred at £15.0724 per share on June 9, 2025.
- Scope Limitation: This filing does not reflect GSK's quarterly or annual financial performance; investors should refer to Form 20-F or earnings releases for company-wide metrics.